Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug

Brazilian Journal of Medical and Biological Research

Volumn 39, Issue 4, 2006, Pages 421-429

  Zuardi, A W ^a   Crippa, J A S ^a   Hallak, J E C ^a   Moreira, F A ^a   Guimaraes F S ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Antipsychotic; Anxiety; Cannabidiol; Cannabinoid; Schizophrenia

Indexed keywords

AMISULPRIDE; ATYPICAL ANTIPSYCHOTIC AGENT; CANNABIDIOL; CANNABIS; CLOZAPINE; DIAZEPAM; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DRONABINOL; HALOPERIDOL; IPSAPIRONE; KETAMINE; NABILONE; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO;

ANIMAL BEHAVIOR; ANXIETY DISORDER; BINOCULAR VISION; BIPOLAR DISORDER; CLINICAL TRIAL; DEPTH PERCEPTION; DRUG BRAIN LEVEL; DRUG INDICATION; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; NEUROCHEMISTRY; NONHUMAN; PSYCHOSIS; REVIEW; SCHIZOPHRENIA; SYMPTOMATOLOGY; TRANQUILIZING ACTIVITY; UNSPECIFIED SIDE EFFECT;

ANIMALIA; CANNABIS; CANNABIS SATIVA;

EID: 33645821022     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/S0100-879X2006000400001     Document Type: Review

References (50)

1. Mikuriya TH (1969). Marijuana in medicine: past, present and future. California Medicine, 110: 34-40.
2. Fankhauser M (2002). History of cannabis in Western Medicine. In: Grotenhermen F & Russo E (Editors), Cannabis and Cannabinoids. The Haworth Integrative Healing Press, New York, 37-51.
3. Martin BR, Mechoulam R & Razdan RK (1999). Discovery and characterization of endogenous cannabinoids. Life Sciences, 65: 573-595.
4. Carlini EA, Santos M, Claussen V et al. (1970). Structure activity relationship of four tetrahydrocannabinols and the pharmacological activity of five semipurified extracts of Cannabis sativa. Psychopharmacologia, 18: 82-93.
5. Grlie L (1976). A comparative study on some chemical and biological characteristics of various samples of cannabis resin. Bulletin on Narcotics 14: 37-46.
6. 9-THC in normal subjects. Psychopharmacology, 76: 245-250.
7. 9-tetrahydrocannabinol. Psychopharmacologia, 33: 53-70.
8. 9-THC-actions by cannabinol and cannabidiol in the rats. Psychopharmacologia, 38: 329-338.
9. 9-tetrahydrocannabinol, H-cannabinol and cannabidiol. Clinical Pharmacology and Therapeutics, 18: 80-83.
10. Bornhein LM, Borys HK & Karler R (1981). Effect of cannabidiol on cytochrome P-450 and hexobarbital sleep time. Biochemical Pharmacology, 30: 503-507.
11. 9-tetrahydrocannabinol. British Journal of Pharmacology, 45: 375-377.
12. 9-tetrahydrocannabinol on operant behavior. Research Communications in Chemical Pathology and Pharmacology, 9: 453-462.
13. 9-tetrahydrocannabinol. Archives Internationales de Pharmacodynamie et de Therapie, 249: 137-146.
14. 9-tetrahydrocannabinol in man. European Journal of Pharmacology, 28: 172-177.
15. 1-tetrahydrocannabinol with cannabinol and cannabidiol following oral administration in man. Assay of cannabinol and cannabidiol by mass fragmentography. Experientia, 37: 1090-1092.
16. Monti JM (1977). Hypnotic-like effects of cannabidiol in the rats. Psychopharmacology, 76: 263-265.
17. Cunha J, Carlini EA, Pereira AE et al. (1980). Chronic administration of cannabidiol to healthy volunteers and epileptic patients. Pharmacology, 21: 175-185.
18. 9-tetrahydrocannabinol are neuroprotective antioxiclants. Proceedings of the National Academy of Sciences, USA, 95: 8268-8273,
19. 9-tetrahydrocannabinol and cannabidiol on serum corticosterone levels in rats. Archives intemationales de Pharmacodynamie et de Therapie, 269: 12-19.
20. Zuardi AW, Guimarães FS & Moreira AC (1993). Effect of cannabidiol on plasma prolactin, growth hormone and cortisol in human volunteers. Brazilian Journal of Medical and Biological Research, 26: 213-217.
21. 9-THC, CBD and mixture of the two cannabinoids. Arquivos de Biologia e Tecnologia, 26: 391-397.
22. Musty RE, Conti LH & Mechoulam R (1984). Anxiolytic properties of cannabidiol. In: Harvey DJ (Editor), Marihuana '84. Proceedings of the Oxford Symposium on Cannabis. IRL Press Limited, Oxford, UK, 713-719.
23. Onaivi ES, Green MR & Martin BR (1990). Pharmacological characterization of cannabinoids in the elevated plus maze. Journal of Pharmacology and Experimental Therapeutics, 253: 1002-1009.
24. Guimarães FS, Chiaretti TM, Graeff FG et al. (1990). Antianxiety effect of cannabidiol in the elevated plus-maze. Psychopharmacology, 100: 558-559.
25. Silveira Filho NG & Tufik S (1981). Comparative effects between cannabidiol and diazepam on neophobia, food intake and conflict behavior. Research Communications in Psychology, Psychiatry and Behavior, 6: 25-26.
26. Zuardi AW, Cosme RA, Graeff FG et al. (1993). Effects of ipsapirone and cannabidiol on human experimental anxiety. Journal of Psychopharmacoly 7: 82-88.
27. Crippa JAS, Zuardi AW, Garrido GE et al. (2004). Effects of cannabidiol (CBD) on regional cerebral blood flow. Neuropsychopharmacology, 29: 417-426.
28. Lipska BK & Weinberger DR (2000). To model a psychiatric disorder in animals: schizophrenia as a reality test. Neuropsychopharmacology, 23: 223-239.
29. Gardner DM, Baldessarini RJ & Waraich P (2005). Modern antipsychotic drugs: a critical overview. Canadian Medical Association Journal, 172: 1703-1711.
30. Baldessarini RJ & Tarazi FI (1996). Brain dopamine receptors: a primer on their current status, basic and clinical. Harvard Review of Psychiatry, 3: 301-325.
31. Hoffman DC & Donovan H (1995). Catalepsy as a rodent model for detecting antipsychotic drugs with extrapyramidal side effects. Psychopharmacology, 120: 128-133.
32. Zuardi AW, Rodrigues JA & Cunha JM (1991). Effects of cannabidiol in animal models predictive of antipsychotic activity. Psychopharmacology, 104:260-264.
33. Malhotra AK, Adler CM, Kennison SD et al. (1997). Clozapine blunts N-methyl-D-aspartate antagonist-induced psychosis: a study with ketamine. Biological Psychiatry, 42: 664-668.
34. Moreira FA & Guimaerães FS (2005). Cannabidiol inhibits the hyperlocomotion induced by psychotornimetic drugs in mice. European Journal of Pharmacology, 512: 199-205.
35. Robertson GS & Fibiger HC (1992). Neuroleptics increase c-Fos; expression in the forebrain: contrasting effects of haloperidol and clozapine. Neuroscience, 46: 315-328.
36. Zuardi AW, Guimarães FS, Guimarães VM et al. (2002). Cannabidiol: possible therapeutic application. In: Grotenhermen F, Russo E & Varo FIN (Editors), Cannabis and Cannabinoids: Pharmacology, Toxicology and Therapeutic Potential. The Haword Interactive Healing Press, New York, 359-369.
37. Guimarães VMC, Zuardi AW, Del Bel EA et al. (2004). Cannabidiol increases Fos expression in the nucleus accumbens but not in the dorsal striatum. Life Sciences, 75: 633-638.
38. Zuardi AW & Guimarães FS (1997). Cannabidiol as an anxiolytic and antipsychotic. In: Mathre ML (Editor), Cannabis in Medical Practice. McFarland & Company, Inc., Jefferson, NC, USA, 133-141.
39. Consroe P, Laguna J, Allender J et al. (1991). Controlled clinical trial of cannabidiol in Huntington's disease. Pharmacology, Biochemistry, and Behavior, 40: 701-708.
40. Moreau JJ (1845). Du Hachisch et de I'Alienation Mentale: Etudes Psychologiques. Librarie de Fortin Mason, Paris, France (English edition: Raven Press, New York, 1972).
41. D'Souza DC, Perry E, MacDougall L et al. (2004). The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: Implications for psychosis. Neuropsychopharmacology, 29: 1558-1572.
42. Rottanburg D, Robins AH, Ben-Aire O et al. (1982). Cannabis-associated psychosis with hypomaniac feature. Lancet, 2: 1364-1366.
43. Schneider U, Borsutzky M, Seifert J et al. (2002). Reduced binocular depth inversion in schizophrenic patients. Schizophrenia Research, 53: 101-108.
44. Leweke FM, Schneider U, Radwan M et al. (2000). Different effects of nabilone and cannabidiol on binocular depth inversion in man. Pharmacology, Biochemistry, and Behavior, 66: 175-181.
45. Krystal JH, Karper LP, Bremner JD et al. (1994). Subanesthetic effects of the noncompetitive NMDA antagonist, ketarnine, in humans. Archives of General Psychiatry, 51: 199-214.
46. Bosi DC, Hallak JEC, Dursun SM et al. (2003). Effects of cannabidiol on (s)-ketamine-induced psychopathology in healthy volunteers. Journal of Psychopharmacology, 17 (Suppl): A55.
47. Zuardi AW, Morais SL, Guimarães FS et al. (1995). Anti-psychotic effect of cannabidiol. Journal of Clinical Psychiatry, 56: 485-486.
48. Zuardi AW, Hallak JEC, Dursun SM et al. (2006). Effect of cannabidiol in non responsive schizophrenia. Journal of Psychopharmacology (in press).
49. Leweke FM, Koethe D, Gerth CW et al. (2005). Cannabidiol as an antipsychotic: a double-blind, controlled clinical trial on cannabidiol vs amisulpride in acute schizophrenics. 2005 Symposium on the Cannabinoids, Burlington, Vermont, International Cannabinoid Research Society. http://CannabinoidSociety.org.
50. Ashton CH, Moore PB, Gallagher P et al. (2005). Cannabinoids in bipolar affective disorder: a review and discussion of their therapeutic potential. Journal of Psychopharmacology, 19: 293-300.